Bioprothetic aortic and pulmonary valves replacement (AVR) via transpical and transcatheter techniques is usually only used in specific patients in whom traditional valve replacement surgery seems to be an unacceptable risk. 

Being able to operate patients with severe aortic atherosclerosis or calcification without the risk of stroke from cross-clamping a calcified aorta is considered a major benefit of this technique.

The avoidance of the use of cardiopulmonary bypass could help to prevent some of the common complications in high-risk patients and allows to treat even patients previously considered inoperable.

Avoiding a full sternotomy may also be cosmetically more acceptable to most patients.